CliffBio
small molecule

JOENJA

LENIOLISIB PHOSPHATE

Loss of exclusivityFebruary 2032latest FDA-listed patent expiry
CompanyPHARMING TECHNOLOGIES BV

Drug detail

Brand nameJOENJA
Active ingredientLENIOLISIB PHOSPHATE
StrengthEQ 70MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2023
Marketing statusRX

Listed patents

PatentExpiresType
8653092February 2032substance, product

Regulatory exclusivity

CodeExpires
ODE-430March 2030
NCEMarch 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

JOENJA patent cliff — loss of exclusivity February 2032 | CliffBio